Table of Contents
Journal of Radiotherapy
Volume 2014, Article ID 941072, 6 pages
Research Article

90Y-DOTA-CHS Microspheres for Live Radiomicrosphere Therapy: Preliminary In Vivo Lung Radiochemical Stability Studies

1Department of Radiology, Weill Cornell Medical College, New York City, NY 10028, USA
2Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33174, USA
3Biomedical Engineering Department, Florida International University, Miami, FL 33174, USA
4Mount Sinai Medical Center, Miami, FL 33140, USA
5Jackson North Medical Center, Miami, FL 33169, USA

Received 12 September 2013; Accepted 25 November 2013; Published 3 February 2014

Academic Editor: Samer Ezziddin

Copyright © 2014 Alejandro Amor-Coarasa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chitosan (CHS) is used to prepare microspheres of 31 ± 8 µm size. Surface modification with p-SCN-Bn-DOTA was performed. A maximum 90Y capacity was found to be 12.1 ± 4.4 µCi/particle. The best obtained labeling yield was 87.7 ± 0.6%. More than 90% in vitro stability was found. Particle in vitro degradation half-life in PBS was found to be greater than 21 days. In vivo studies with 90Y-DOTA-CHS showed more than 95% of the injected activity (decay corrected) in the lungs 24 hours after tail vein administration. 90Y-DOTA-CHS in vivo label stability was superior to resin microspheres. The addition of p-SCN-Bn-DOTA served as a radioprotectant for bone marrow as the 5% 90Y released, during the first 24 hours, was quickly eliminated via urine.